Systemic drug therapy in the obese patient with psoriasis

Should a patient’s Body Mass Index (BMI) influence the choice of a systemic drug in the treatment of psoriasis and psoriatic arthritis?  A recent report suggests that the answer is ‘Yes’1.

There is a strong and consistent association between obesity and psoriasis; obese patients are more likely to develop psoriasis and its severity increases with …

COVID-19 updated guidance on shielding

Clinically extremely vulnerable groups

With the changing COVID-19 restrictions, you may like to know what the definition of clinically extremely vulnerable groups are

People who are defined as clinically extremely vulnerable are at very high risk of severe illness from coronavirus. There are 2 ways you may be identified as clinically extremely…

Coronavirus (COVID-19) statistics

As the daily news appears to report the rise of positive cases and testing, you may like to read the official statistics from the Government website 

The website includes the numbers of cases, deaths and tests. The site also includes graphs and cumulative data. There is also a breakdown for all four UK nations (England, Scotland, Wales and…

Skin 'n' Bones Connection #51

I'm pleased to share our latest journal with you. Lockdown may have affected many activities, but we were determined to get issue 51 of Skin 'n' Bones Connections out to subscribers. In this edition we cover a number of issues, including: Global Psoriasis Atlas, psoriasis and migraine, psoriasis and depression, plus much more.

The journal is…

Show More